All Outputs (3)

A new standard for assessing asbestos exposure and its consequences? (2016)
Journal Article
Mutti, L. (2016). A new standard for assessing asbestos exposure and its consequences?. Occupational and Environmental Medicine, 73(10), 709-710. https://doi.org/10.1136/oemed-2016-103693

Comment on the original article: Gilham C, Rake C, Burdett G, et al. Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occup Environ Med 2015; doi: 10.1136/oemed-2015-103074.

Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells (2016)
Journal Article
Fiorillo, M., Lamb, R., Tanowitz, H., Mutti, L., Krstic- Demonacos, M., Cappello, A., …Lisanti, M. (2016). Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget, 7(23), 34084-34099. https://doi.org/10.18632/oncotarget.9122

Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone... Read More about Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.

Targeting hypoxic response for cancer therapy (2016)
Journal Article
Paolicchi, E., Gemignani, F., Krstic-Demonacos, M., Dedhar, S., Mutti, L., & Landi, S. (2016). Targeting hypoxic response for cancer therapy. Oncotarget, 7(12), https://doi.org/10.18632/oncotarget.7229

Hypoxic tumor microenvironment (HTM) is considered to promote metabolic changes, oncogene activation, and epithelial mesenchymal transition, and resistance to chemo- and radio-therapy, all of which are hallmarks of aggressive tumor behavior. Cance... Read More about Targeting hypoxic response for cancer therapy.